Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: deoxycholic acid injection, deoxycholic acid, ATX-101
Kybella contains synthetic deoxycholic acid, a naturally occurring bile acid. When injected into submental fat, deoxycholic acid physically disrupts cell membranes and causes cytolysis. The FDA-approved product is a clear, colorless, sterile 10 mg/mL solution supplied in 2 mL single-use vials containing 20 mg of deoxycholic acid.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
FDA-labeled administration uses an area-adjusted dose of 2 mg/cm², with each injection containing 2 mg in 0.2 mL and spaced 1 cm apart; a single treatment may include up to 50 injections and 100 mg total in up to 10 mL. Up to 6 treatments may be administered at intervals of at least 1 month. In phase III randomized placebo-controlled studies of ATX-101, investigational regimens included 1 or 2 mg/cm² injected into submental fat for up to 4 treatment sessions approximately 28 days apart. These details are provided as neutral study/reference information and are not individualized treatment instructions.
Supplementary research context only. Not medical advice or a treatment recommendation.
Chemical name: 3α,12α-dihydroxy-5β-cholan-24-oic acid; molecular formula: C24H40O4; molecular weight: 392.57 g/mol; UNII: 005990WHZZ; RxCUI: 1649980 for Kybella 20 mg in 2 mL injection; NDC package identifiers include 61168-101-01, 61168-101-03, and 61168-101-04.
The FDA label identifies injection-site edema or swelling, hematoma, pain, numbness, erythema, and induration as common adverse reactions. The product is contraindicated in the presence of infection at the injection area. Use outside the submental region is not approved or recommended in the FDA labeling.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Kybella or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.